No, patients with chronic kidney disease should NOT receive Toradol (ketorolac) injections.
Ketorolac is contraindicated or should be avoided in patients with CKD due to significant risk of acute kidney injury (AKI) and further deterioration of renal function.
The Evidence Against Ketorolac in CKD
High-Quality Recent Data
The most compelling evidence comes from a 2025 propensity-matched study demonstrating that in patients with pre-existing CKD, ketorolac administration was associated with a 12.7% incidence of AKI compared to only 2.0% without ketorolac (p=0.041) 1. This represents more than a 6-fold increase in AKI risk. Importantly, patients with normal renal function showed no increased AKI risk (2.0% vs 1.9%), indicating the harm is specifically concentrated in the CKD population 1.
Mechanism and Historical Evidence
NSAIDs like ketorolac inhibit prostaglandin synthesis, which is critical for maintaining renal perfusion in patients with compromised kidney function. Multiple case reports from the 1990s documented acute renal failure following ketorolac administration, particularly in elderly patients and those with pre-existing renal impairment 2, 3, 4, 5. These cases consistently showed:
- Reversible oliguric renal insufficiency
- Mean serum creatinine increases from 1.2 mg/dL to 2.9 mg/dL
- Recovery after discontinuation (mean 2.3 days)
Risk Factors That Amplify Danger
Patients with CKD often have multiple compounding risk factors that make ketorolac particularly hazardous:
- Advanced age (common in CKD populations)
- Volume depletion (frequently present perioperatively or with diuretic use)
- Cardiovascular disease (present in 5 of 6 patients in one case series) 5
- Concomitant medications (ACE inhibitors, ARBs, diuretics - all standard CKD therapies per KDIGO guidelines) 6
Clinical Algorithm for Pain Management in CKD
When a patient with ANY stage of CKD needs analgesia:
- Check baseline renal function - Know the eGFR and creatinine
- Avoid ketorolac entirely if eGFR <60 mL/min/1.73m² or any CKD diagnosis
- Alternative analgesics:
- Acetaminophen (dose-adjust if severe CKD)
- Opioids (with appropriate dose adjustment for renal clearance)
- Regional/local anesthesia without NSAIDs in the cocktail
- If NSAID absolutely necessary in mild CKD (eGFR >60), use shortest duration possible with close monitoring
Critical Pitfalls to Avoid
- Don't assume "just one dose" is safe - Even short-term ketorolac (mean 2-3 doses) caused AKI in reported cases 3, 5
- Don't rely on "normal" baseline creatinine in elderly patients - Age-related muscle loss masks true GFR; calculate eGFR
- Don't use in perioperative settings with CKD - Third-spacing and volume shifts compound the risk 4
- Don't forget drug interactions - RAS inhibitors (ACEi/ARBs), which are standard CKD therapy per KDIGO guidelines 6, further increase NSAID nephrotoxicity risk
The Bottom Line
While ketorolac may be effective for pain control in patients with normal renal function 7, the risk-benefit ratio is unacceptable in CKD patients. The 6-fold increased AKI risk 1, combined with the reversible but potentially serious nature of NSAID-induced renal failure 2, 3, 4, 5, makes alternative analgesics the clear choice. This is not a "use with caution" scenario - it's an avoid scenario.